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ABSTRACT

Introduction Evidence supporting use of continuous
glucose monitoring in type 2 diabetes treated with basal
insulin is unclear. This real-world study aimed to assess
the impact on glycated hemoglobin (HbA1c) of flash
glucose monitoring use in adults with type 2 diabetes
managed with basal insulin.
Research design and methods Medical records were
reviewed for adult individuals with type 2 diabetes
using basal insulin for ≥1 year with or without additional
antihyperglycemic medication, HbA1c 8.0%–12.0% prior
to FreeStyle Libre Flash Glucose Monitoring use for ≥90
days and an HbA1c measurement recorded between 90
and 194 days after device use. Exclusion criteria included
utilization of bolus insulin. Meta-analysis data are from the
current study (USA) and a similar Canadian cohort.
Results Medical record analysis (n=100) from 8 USA
study sites showed significant HbA1c decrease of
1.4%±1.3%, from 9.4%±1.0% at baseline to 8.0%±1.2%
after device use, p<0.0001 (mean±SD).
Meta-analysis of medical records from USA and Canada
sites (n=191) showed HbA1c significantly decreased by
1.1%±0.14% (mean±SE), from baseline 9.2%±1.0%
to 8.1%±1.1%, p≤0.0001, with moderate to high
heterogeneity between sites (Q=43.9, I2=74.9, p<0.0001)
explained by differences in baseline HbA1c between sites.
The HbA1c improvement in both groups was observed by
age group, body mass index, duration of insulin use and
sex at birth.
Conclusions In a real-world retrospective USA study
and a meta-analysis of a larger USA and Canada cohort,
HbA1c significantly reduced in basal insulin-treated type 2
diabetes, without bolus insulin initiation and following the
commencement of ﬂash glucose monitoring technology.

INTRODUCTION
The American Diabetes Association (ADA)
recognizes that glycemic management is
primarily assessed by glycated hemoglobin
(HbA1c) measurements.1 HbA1c has been
the principal clinical marker used in clinical
trials to demonstrate the benefits of improved
glycemic management.1 In regard to continuous glucose monitoring (CGM), the ADA
acknowledges that this technology has an

Significance of this study
What is already known about this subject?
► To date, the reported benefit of continuous glucose

monitoring (CGM) use in type 2 diabetes is largely
limited to intensive insulin regimens.
► Evidence supporting use of this type of glucose
monitoring technology to support management of a
basal insulin regimen is limited.

What are the new findings?
In this real-world observational review study in the USA
and meta-analysis of a larger USA and Canada cohort:
► Glycated hemoglobin (HbA1c) significantly reduced
in both groups 3–6 months after commencing ﬂash
glucose monitoring technology use in type 2 diabetes treated with basal insulin and without initiating
bolus insulin.
► HbA1c reduction is supported by the sensitivity analysis demonstrating consistent HbA1c values.
► HbA1c improvement was observed in both groups by
age group, body mass index, duration of insulin use
and sex at birth; over half of the participants had a
final HbA1c <8%.

How might these results change the focus of
research or clinical practice?
► HbA1c is the gold standard clinical marker used to

demonstrate improved glycemic control.
► This finding may suggest that the use of CGM in type

2 diabetes treated with basal insulin has the potential to be a valuable tool to support the improvement
of glucose control.

important role in glucose management for
diabetes and notes that the reported benefit
of CGM in type 2 diabetes is to date largely
limited to its use with intensive insulin regimens.2 While there is increasing evidence
to support CGM use in this population,3–6
reported evidence of CGM use to support
management of a basal insulin regimen is
more limited.7–11 The aim of this real-world
study was to evaluate the impact on HbA1c
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after the introduction of flash glucose monitoring use in
type 2 diabetes managed with basal insulin in diabetes
centers in the USA. Analysis of a larger cohort combining
data from the USA and Canada is also reported.
MATERIALS AND METHODS
The methodology and population of the current study
are analogous to those described by Elliott et al.10 The
current retrospective non-interventional single-arm chart
review study was conducted in diabetes centers in the
USA. The clinics each performed a database search for
potential medical records to be included in the review.
Paper or electronic medical records were included for
adult individuals (18 years or more) with type 2 diabetes
managed with analogue or isophane basal insulin therapy
for 1 year or more, with or without additional oral antihyperglycemic medication and non-
insulin injection
therapy, the FreeStyle Libre Flash Glucose Monitoring
System (Abbott Diabetes Care, Alameda, California,
USA) had been used for at least 90 days when the data
were collected, an HbA1c measurement between 8.0%
and 12.0% was recorded in the medical notes within
90 days before device use commenced and an HbA1c
measurement was recorded >90 and <194 days after initiation of device use. The definition of a baseline HbA1c
was a result recorded not more than 90 days before
device use commenced (the index date). If additional
baseline HbA1c measurements were available, the one
nearest to the index date was used. The definition of a
follow-up HbA1c measurement was a result recorded not
less than 90 and no more than 194 days after the index
date. If additional follow-up HbA1c measurements were
available, the measurement closest to the index date plus
135 days was used. All HbA1c measurements used in the
analysis had been recorded in the medical records and
were from a laboratory or point-of-care test. In addition
to baseline HbA1c concentrations, the study sites also
extracted information that had been recorded in the
medical records prior to initiation of device use for age,
blood pressure, concomitant disease, complications of
diabetes, time using insulin, height, glucose-
lowering
medications, sex and weight.
Medical records were not eligible for inclusion in the
study for anyone who was using bolus or biphasic insulin,
pregnant, undergoing dialysis therapy or was a participant in another study that might impact their glucose
results or management during use of the device.
Analysis of the extracted data from the medical records
established final eligibility for inclusion in the analysis.
Additional data for the meta-analysis were from a retrospective non-interventional single-arm chart review study
in Canada, as noted above.10
Outcomes
The primary end point for the current study and the
meta-analysis was evaluation of change in HbA1c from
the index date to a follow-up HbA1c measurement taken
2

after device use was commenced (between 90 and 194
days after). Analysis of the primary end point was also
performed for the subgroups: age (<65 and ≥65 years),
HbA1c at baseline (<9% and ≥9%), body mass index
(BMI (<30 and ≥30 kg/m2)), duration of insulin use (<4
and ≥4 years), rate of daily blood glucose testing and sex
at birth. As this was a retrospective chart review study,
safety and adverse event information were not collected.
Statistical analysis
A paired t-test was used to assess differences between
HbA1c measurements recorded 90 to 194 days after
starting device use and at baseline. A total of 78 medical
records are needed to detect a change in HbA1c of
0.35% (3.8 mmol/mol) within each country with a power
of 80% (at p<0.05), based on an SD of change in HbA1c
of 1.1%.12 For the primary end point, if more than one
HbA1c test fulfilled the criteria then the test nearest to
the device start date +135 days was used. Meta-analysis of
change in HbA1c was performed using a random effects
model on patient record level data, using center as a
random effect. Cochran’s heterogeneity statistic (Q) and
the I2 statistic were calculated.13 A meta-regression analysis was performed on baseline HbA1c with center as a
random effect. Subgroups were compared using analysis
of covariance on baseline HbA1c. Qualified statisticians
at Abbott Diabetes Care (UK) performed the data analysis using V.9.4 of SAS (or higher).
RESULTS
The USA chart review data were extracted from medical
records between November 2017 and July 2020. A total
of 131 medical records from both primary care (Internal
Medicine and Family Practice) and more specialist
diabetes centers were identified by 8 study sites. Of these,
11 did not meet the inclusion criteria, 6 had a baseline HbA1c outside the stated range of 8.0%– 12.0%,
3 had not used basal insulin for at least 1 year prior to
starting device use (or the duration was unknown) and
2 had bolus insulin therapy use recorded. In addition,
6 medical records did not have a baseline HbA1c within
90 days of starting device use, 12 medical records did not
have a HbA1c result logged between 90 and 194 days
after starting to use the device and 2 medical records
had neither a baseline nor a final HbA1c result. The total
number of medical records included in the USA primary
end point analysis was 100.
The mean age at the start of device use was 56.0±10.3
years (mean±SD), baseline HbA1c was 9.4%±1.0% and
52 (52%) of medical records were for male individuals.
For the meta-analysis, a total of 234 medical records
were identified by 14 study sites in the USA (n=8) and
Canada (n=6) from November 2017 to July 2020. Fourteen medical records did not meet the eligibility criteria,
9 did not have a baseline HbA1c within 90 days of starting
the device, 14 did not have an HbA1c result 90–194 days
after starting the device and 3 did not have a baseline
BMJ Open Diab Res Care 2022;10:e002590. doi:10.1136/bmjdrc-2021-002590
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Table 1 Demographics and baseline characteristics for the US and combined cohorts
US cohort

Combined group cohort

N

n=100

n=191

Male n (%)

52 (52.0)

115 (60.2)

48 (48.0)

76 (39.8)

Female n (%)
Age (years)

Mean±SD

56.0±10.3

60.0±11.3

BMI (kg/m2)

Mean±SD

36.1±7.8 (n=97)

33.5±8.2 (n=184)

Duration of insulin use (years)

Mean±SD

4.5±3.5

4.3±3.3

Baseline HbA1c (%)

Mean±SD

9.4±1.0

9.2±1.0

Baseline HbA1c (mmol/mol)

Mean±SD

79.2±11.1

76.8±10.7

96 (96.0)

183 (95.8)

82 (82.0)

151 (79.1)

28 (28.0)

85 (44.5)

 Sulfonylureas

40 (40.0)

70 (36.6)

 DPP4 inhibitors

11 (11.0)

46 (24.1)

 Thiazolidinediones

4 (4.0)

5 (2.6)

GLP1 agonists

56 (56.0)

100 (52.4)

Additional antihyperglycemic
Any oral antihyperglycemic medication
medications at time of starting flash
 Metformin
glucose monitoring, n (%)
 SGLT inhibitors

BMI, body mass index; DPP4, dipeptidyl peptidase‐4; GLP1, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; SGLT, sodium-glucose
cotransporter.

nor a final HbA1c result. Three records were retrospectively excluded as bolus insulin was used during the study
period. The total number of medical records included in
the meta-analysis was 191.
For the USA and Canda combined cohort, the mean
age at start of device use was 60.0±11.3 years (mean±SD),
baseline HbA1c was 9.2%±1.0% and 115 (60.2%)
medical records were for male individuals. Baseline characteristics and demographics, and medical history from
the medical records for both the USA cohort and the
combined USA and Canada cohort are listed in tables 1
and 2, respectively.
Baseline characteristics for the Canada-only cohort are
listed in online supplemental table S2.
Primary end point
In the current USA study, baseline HbA1c (mean±SD)
significantly reduced between 90 and 194 days after
starting device use by 1.4%±1.3% from 9.4%±1.0% to
8.0%±1.2%, p<0.0001 (figure 1 and online supplemental
table S1).
In the meta-
analysis of combined USA and Canada
data, baseline HbA1c significantly reduced 90–194 days
after starting device use by 1.1%±0.14% (mean±SE)
from 9.2%±1.0% to 8.1%±1.1% (mean±SD), p≤0.0001
(figure 1 and online supplemental table S1). Moderate to
high heterogeneity between centers (Q=43.9, I2=74.9%,
p<0.0001) was observed.
The meta-regression of change in HbA1c on baseline
HbA1c showed a slope of −0.66%±0.078% per % baseline HbA1c (mean±SE) and low heterogeneity with an I2
value of 1.6% (Cochran’s Q=10.2, p=0.4267).
BMJ Open Diab Res Care 2022;10:e002590. doi:10.1136/bmjdrc-2021-002590

Sensitivity analysis
For the USA cohort, the mean number of days between
initiation of device use (index date) and the final HbA1c
value used in the analysis was 131.7 days (median 132.0).
A sensitivity analysis was performed on the primary end
point of change in HbA1c for different time windows of
the final HbA1c value (121–149 days, 107–163 days and
90–180 days) and the change in HbA1c remained similar
(p<0.0001 for all time windows, figure 2).
When baseline HbA1c measurements were compared
with follow-
up HbA1c measurements for each month
of the 3–6 months period after device use was initiated
(months 3–4, 4–5, 5–6 and 5.5–6.5), HbA1c change
remained significant (figure 2).
Subgroup analysis
For the current USA study and the larger cohort of both
countries combined, prespecified subgroup analysis
showed HbA1c improvement by age group (<65 and ≥65
years), baseline HbA1c (<9% and ≥9%), BMI (<30 and
≥30 kg/m2), duration of insulin use (<4 and ≥4 years)
and sex at birth.
In the 2 countries combined cohort, there was a
similar change in HbA1c between the subgroups for age
(p=0.0900), BMI (p=0.2811), duration of insulin use
(p=0.4057), blood glucose testing frequency (p=0.1495)
or sex at birth (p=0.6966). All subgroup analysis results
are shown in figure 3.
In the current USA study, recorded data for frequency
of self-monitoring of blood glucose (prior to flash glucose
monitoring use) were available from 55% (n=55/100) of
the US medical records and 56% (n=107/191) of the
USA and Canada group medical records (online supplemental table S1).
3
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Table 2 Medical history at baseline for the US and
combined cohorts
US cohort

Combined
group cohort

N (%)

n=100

n=191

CVD complications

19 (19.0)

54 (28.3)

 Myocardial infarction

4 (4.0)

16 (8.4)

 Angina

6 (6.0)

25 (13.1)

 Peripheral vascular disease

6 (6.0)

11 (5.8)

 Stroke

4 (4.0)

9 (4.7)

 Heart failure

3 (3.0)

6 (3.1)

 Atrial fibrillation

0 (0.0)

5 (2.6)

 Left ventricular hypertrophy

1 (1.0)

10 (5.2)

Renal complications

13 (13.0)

60 (31.4)

 Microalbuminuria

12 (12.0)

57 (29.8)

 Gross proteinuria

2 (2.0)

7 (3.7)

 End-stage renal disease

1 (1.0)

1 (0.5)

Retinopathy complications

15 (15.0)

27 (14.1)

 Background diabetic
retinopathy

13 (13.0)

22 (11.5)

 Proliferative diabetic
retinopathy

3 (3.0)

5 (2.6)

 Severe vision loss

0 (0.0)

1 (0.5)

Foot ulcer Complications

2 (2.0)

5 (2.6)

 Uninfected ulcer

0 (0.0)

1 (0.5)

 Infected ulcer

0 (0.0)

1 (0.5)

 Healed ulcer

2 (2.0)

4 (2.1)

 Amputation
Cataract
Macular oedema

0 (0.0)

1 (0.5)

10 (10.0)

30 (15.7)

5 (5.0)

5 (2.6)

Neuropathy

17 (17.0)

35 (18.3)

Depression

23 (23.0)

35 (18.3)

Figure 1 Change in glycated hemoglobin (HbA1c) (%)
between baseline and at 3–6 months (90–194 days) after
commencing flash glucose monitoring.

is supported by the observed HbA1c reduction in the
larger meta-
analysis cohort and the sensitivity analysis
demonstrating consistent HbA1c values, which was also
reported separately for the Canada cohort.10
The observed significant decrease in HbA1c in the USA
cohort is supported by an earlier prospective randomized
controlled trial in intermittent use of real-time CGM in

CVD, cardiovascular disease.

The majority of this subgroup reported testing twice
per day or less (n=42/55 and n=89/107, respectively).
Baseline HbA1c reduced by 1.4%±1.0% and 1.2%±1.1%
(mean±SD), respectively, p<0.0001 for both groups. For
more than 2 tests per day (n=13 and n=18), baseline
HbA1c fell by 0.9%±1.5% (p=0.0579) in the USA group
and by 1.0%±1.5% (p=0.0104) in the larger USA and
Canada group.
Post hoc analysis demonstrated 56% (n=56/100) of
USA participants had a final HbA1c <8%.
DISCUSSION
This USA retrospective chart review clinical study
observed significant improvement in HbA1c 3–6 months
after use of flash glucose sensor monitoring technology
was commenced in individuals with type 2 diabetes
managed with basal insulin. Bolus insulin initiation and
use were not permitted either before or during the study.
The unequivocal achievement of the primary end point
4

Figure 2 CI plot of change in glycated hemoglobin (HbA1c)
(%) with narrower time windows around day 135 and change
in HbA1c (%) for each month of the 3–6 months after
commencing flash glucose monitoring for the US cohort.
BMJ Open Diab Res Care 2022;10:e002590. doi:10.1136/bmjdrc-2021-002590
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Figure 3 Change in glycated hemoglobin (HbA1c) by baseline HbA1c, age, sex at birth, duration of insulin use, body mass
index (BMI) and blood glucose (BG) testing frequency for the US cohort (A) and the combined group cohort (B).

a type 2 diabetes cohort using either basal insulin and/
or antihyperglycemic medications, which demonstrated
a 1.2% (within group) HbA1c reduction after 6 months.7
In this mixed cohort, the majority of these participants
were non-insulin users who may show a more pronounced
change in HbA1c with CGM.9 However, a recent randomized controlled trial in a similar cohort to the current
study reported a comparable within-group HbA1c reduction at 8 months in the CGM group.11
The current chart review study supports reported findings by studies in flash glucose monitoring with a similar
population and methodology from Canada (0.8%)10 and
the USA (0.6%).9 In 2021, Wright et al reported a 1.1%
reduction in type 2 diabetes managed with basal insulin
therapy and flash glucose monitoring use.8 The observed
reduction in HbA1c in the current study is consistent
with other studies in flash glucose monitoring and CGM
in type 2 diabetes with multiple insulin injection therapy
(MDI), which have demonstrated HbA1c reductions of
0.8%–0.9%.4–6
The current meta-analysis of the larger USA and Canada
combined cohort adds to other recent meta-
analyses.
These included randomized controlled trials and showed
an overall improvement in HbA1c of 0.26%–0.56% in
adults with diabetes using flash glucose monitoring and
0.42% in type 2 diabetes only.14 15 The meta-analysis from
Castellana et al15 found that a 0.4% decrease in HbA1c was
associated with each 1% increase in baseline levels over
7.2%, which correlates with the observed improvement
in HbA1c.14 The observed moderate to high heterogeneity was likely due to differences in the baseline HbA1c
measurements between centers.
BMJ Open Diab Res Care 2022;10:e002590. doi:10.1136/bmjdrc-2021-002590

Significant change in HbA1c was demonstrated in the
current study and the meta-analysis data sets regardless
of age group (figure 3 and online supplemental table
S1). The REPLACE (Flash Glucose-Sensing Technology
as a Replacement for Blood Glucose Monitoring for the
Management of Insulin-Treated Type 2 Diabetes) study,
a randomized controlled study in use of this monitoring
technology and type 2 diabetes managed with MDI,
demonstrated a decrease in HbA1c only in individuals <65
years of age.3 Haak et al3 speculated that a more cautious
approach to therapy adjustments in the older participants
due to the risk of hypoglycemia may have been a factor.
The finding in the current studies for the age subgroups
contrasts with this and supports recent studies showing
benefit from use of this technology irrespective of age in
individuals with type 2 diabetes managed with MDI.5 6
The observed change in HbA1c was more marked for
HbA1c levels >9%. A greater reduction in HbA1c from a
higher baseline measurement has been observed in other
studies in flash glucose monitoring and type 2 diabetes
managed with either insulin or non-insulin therapies.5 6 8
At baseline, the most common oral antihyperglycemic medication used with basal insulin was metformin
followed by a sulfonylurea for the USA cohort and
a sodium-
glucose cotransporter (SGLT) inhibitor in
the Canada cohort. The use of SGLTs inhibitors in the
USA cohort (28%) was similar to a report of national
prescribing trends16 and lower than in the Canada
cohort (62%). Dipeptidyl peptidase‐4 (DPP4) inhibitor
prescribing was also lower in the USA group (11%) than
the Canada group (39%) and compared with national
prescribing trends.17 Use of glucagon-
like peptide-
1
5
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receptor agonists (GLP1 agonists) was similar in both
countries as was the low use of thiazolidinedione therapy
reflecting the overall decreasing trend for prescribing
this medication.18 Details of antihyperglycemic medications for the Canada-only cohort are listed in online
supplemental table S2.
The baseline medical history and the prevalence of
cardiovascular disease, angina and stroke, depression and
renal disease in the current study (table 2) are broadly
similar to other studies in this population.6 17 19 Baseline
demographics and characteristic data for age and use
of basal insulin were also typical of patients with type 2
diabetes.7 20–22 Mean baseline HbA1c at 9.4% confirms
a trend for therapeutic inertia and general tolerance of
suboptimal glycemic control in type 2 diabetes.23 24 Mean
BMI was >30 kg/m2 in the current study reflecting the
high prevalence of obesity in the USA and its association
with type 2 diabetes.21 25 26
Achieving glycemic targets in type 2 diabetes remains
one of the key goals of diabetes management. Review of
glucose control and titration of basal-only insulin therapy
is generally supported by an HbA1c measurement and
blood glucose testing results.1 The optimum frequency
of self-
monitoring in this population is imprecise. In
the present study and the meta-analysis, the majority of
medical records showed a daily testing frequency of 2
tests or less per day. This minimal utilization of fingerstick glucose monitoring by an individual does not
appear to automatically influence HbA1c reduction with
flash glucose monitoring use.6 10
Study strengths and limitations
A limitation of this study is the single-arm retrospective
chart review methodology which, by definition, precludes
a control group. Recent randomized controlled trials
in CGM and type 2 diabetes managed with either MDI
or basal insulin therapy reported change in HbA1c in
the control arm of up to 0.6%.4 5 11 Speculatively, if this
indicates potential study effect, the observed change in
HbA1c would remain clinically relevant in the present
study and meta-analysis.
The methodology prevented more individualized
data collection and although bolus insulin use was
excluded before and during the data collection period,
the potential impact of any additional oral medications
is unknown. Therefore, the observed HbA1c reduction
following initiation of flash monitoring may be due to
a combination of different factors. Basal insulin dose
titration, oral medication adjustments, clinical contact
and behavior or lifestyle modifications, supported
by device use, likely all contributed to achieving the
primary end point. The use of glucose reports, such
as the ambulatory glucose profile, as an educational
resource for clinicians and patients to use together at
review visits has been reported by prospective studies
in flash glucose monitoring use in type 2 diabetes.3 27
Correspondingly, a strength of the study’s retrospective, pragmatic methodology is the lack of mandated
6

glucose management or study administration during
clinical interactions resulting in negligible impact on
selection for study inclusion and clinical care during
the study. These factors, together with the participant
demographics and characteristics, which are typical
of the individuals with type 2 diabetes, suggest the
observed finding may be generalized and applied in
other clinical settings. The length of the current study
is potentially a limitation as the observed change in
HbA1c may not be sustained after 6 months. However,
the breakdown for change in HbA1c for each month
after a minimum of 3–6 months use of this technology
suggests that the change is durable. Vigersky et al
reported that HbA1c reduction following intermittent
CGM use in a mixed cohort of type 2 diabetes managed
with basal insulin or non-insulin therapies was significant at 12 months.7 More recently, Miller et al reported
HbA1c improvement was sustained at 12 months in
type 2 diabetes managed with basal insulin and using
flash glucose monitoring.9
The current study and meta-analysis add to the growing
evidence for use of this technology in type 2 diabetes.
Bolus insulin was not initiated during the study and
the observed improvement in HbA1c is comparable
to the expected impact on glucose control from basal
insulin initiation in insulin-
naïve type 2 diabetes.21
However, it should also be acknowledged that despite
the pronounced change in the HbA1c level, it remained
above the ADA recommended target for this cohort.1 As
an HbA1c level of >8% is an indication of basal and postprandial hyperglycemia,28 further studies in management
of type 2 diabetes with all therapies and CGM technology
are warranted.11

CONCLUSION
In conclusion, significantly reduced HbA1c was retrospectively observed following commencement of ﬂash
glucose monitoring technology in type 2 diabetes treated
with basal insulin and without prandial insulin use.
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